[Skip to Content]
[Skip to Content Landing]
Citations 0
Health Agencies Update
December 24/31, 2003

Autoantibodies Predict Lupus

JAMA. 2003;290(24):3186. doi:10.1001/jama.290.24.3186-a

Clinical studies of testosterone for the treatment of age-related conditions in men aged 65 years or older should go forward, according to a committee of the Institute of Medicine of the National Academies. But the group recommended that only a limited number of participants should be included, and that trials should focus on determining the efficacy and potential benefits of the therapy.

The committee said that a larger trial to study long-term risks and effectiveness should be initiated only if substantial benefits can be demonstrated in initial, short studies. The committee's report also said that studies should include only older men who are not at risk of developing prostate cancer, who have been diagnosed as having low testosterone levels, and who have at least one symptom that could be alleviated by therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview